Inventor · disambiguated record
Sebastian Fenn
Also filed as: FENN SEBASTIAN
12 granted patents·17 pending applications·30 citations·filing 2014–2025
87Inventor score
Files withHOFFMANN LA ROCHE29
Top patents by PatentIndex Score
29 records- 0195US10941205B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 9, 2021·10 cites·13 claims
- 0291US11603411B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Mar 14, 2023·9 cites·5 claims
- 0390US12030952B2Bispecific anti-human CD20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Jul 9, 2024·1 cites·10 claims
- 0488US11787868B2Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·1 cites·5 claims
- 0587US10434184B2Anti-TPBG antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Granted Oct 8, 2019·3 cites·22 claims
- 0685US2025297025A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2025·Application pending·0 cites
- 0783US2023365702A1Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0883US2024294642A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 0982US11421022B2Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereofHOFFMANN LA ROCHE·Filed 2014·Granted Aug 23, 2022·4 cites·3 claims
- 1082US2024317879A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1181US12358997B1Bispecific anti-human A-beta/anti-human transferrin receptor antibodiesHOFFMANN LA ROCHE·Filed 2025·Granted Jul 15, 2025·0 cites·2 claims
- 1281US2023183349A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2023·Application pending·0 cites
- 1380US10106612B2Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereofHOFFMANN LA ROCHE·Filed 2014·Granted Oct 23, 2018·2 cites·8 claims
- 1479US2025051456A1Anti-hla-g antibodies and methods of use thereofHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1578US2023143310A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1673US2023220110A1Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereofHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1767US11732036B2Antibody that binds to VEGF-A and ANG2 and methods of useHOFFMANN LA ROCHE·Filed 2021·Granted Aug 22, 2023·0 cites·9 claims
- 1866US2025163139A1Antibody that binds to vegf-a and il6 and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 1965US11407836B2Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereofHOFFMANN LA ROCHE·Filed 2018·Granted Aug 9, 2022·0 cites·4 claims
- 2065US2020216554A1Bispecific anti-human cd20/human transferrin receptor antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2164US12157770B2Anti-HLA-G antibodies and methods of use thereofHOFFMANN LA ROCHE·Filed 2020·Granted Dec 3, 2024·0 cites·11 claims
- 2262US2019382489A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2018·Application pending·0 cites
- 2356US2017247454A1Anti-pd1 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Application pending·0 cites
- 2456US2021147554A1Multispecific antibodies and use thereofHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 2556US2020108154A1Anti-tpbg antibodies and methods of useHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2655US2022002397A1Method for improving inhibition of vegf-binding to vegf-r1 of an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 2754US2022389116A1Antibodies for chelated radionuclidesHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2849US11820816B2Anti-VEGF antibodies and methods of useHOFFMANN LA ROCHE·Filed 2020·Granted Nov 21, 2023·0 cites·9 claims
- 2949US2022267463A1Antibodies which bind to cancer cells and target radionuclides to said cellsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Sebastian Fenn files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →